Early vs Late Initiation of Extracorporeal Membrane Oxygenation: Protocol for a Prospective, Randomized, Multicenter Study.

backgroundAcute respiratory distress syndrome (ARDS) is characterized by severe inflammatory lung injury leading to life-threatening hypoxemia. Standard treatment includes lung-protective mechanical ventilation and adjunctive measures, while veno-venous extracorporeal membrane oxygenation (vvECMO) is used as a rescue therapy in refractory cases. However, the optimal timing for initiation of vvECMO remains uncertain, with official recommendations identifying it as a rescue therapy, while emerging evidence suggests that earlier implementation of vvECMO during the disease course might provide benefits.

objectiveThe ELIEO (Early vs Late Initiation of vvECMO) trial aims to determine whether early initiation of vvECMO improves survival and clinical outcomes compared with a conventional strategy in patients with severe ARDS.

methodsELIEO is a prospective, randomized, multicenter clinical trial enrolling 508 adult patients with severe ARDS. Participants will be randomized to one of two groups: (1) early vvECMO initiation within 24 hours after admission to the intensive care unit of an extracorporeal membrane oxygenation center or (2) conventional management according to ARDS Network guidelines, with vvECMO used only as rescue therapy. All-cause mortality at day 90 will serve as the primary outcome and will be analyzed using a 2-sided log-rank test within an O'Brien-Fleming group-sequential design. Secondary end points include Sequential Organ Failure Assessment scores, functional status at days 28 and 90, bleeding events, and intensive care unit-related complications, which will be analyzed using appropriate regression and nonparametric methods, with adjusted Cox models for sensitivity analyses.

resultsPatient recruitment started on March 1, 2025, and is ongoing; study completion is expected in August 2028. An interim analysis is planned after the 94th patient has been enrolled. The trial is designed to evaluate whether early initiation of vvECMO reduces 90-day mortality and improves organ function and functional recovery compared with a conventional rescue strategy. Results will be reported after completion of enrollment and follow-up. As of May 2026, a total of 9 patients have been recruited.

conclusionsThe ELIEO trial will provide robust evidence regarding the optimal timing of vvECMO initiation in patients with severe ARDS. The findings may influence clinical decision-making, resource allocation, and organizational strategies for the management of ARDS in specialized intensive care settings.

trial registrationClinicalTrials.gov NCT04208126; https://clinicaltrials.gov/study/NCT04208126. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/86652.